Skip to main content

Samsara BioCapital — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$14.2B
Total invested
$107.7M
Avg. check
16
Industries
Biotechnology 23Health Care 14Therapeutics 9Medical 8Biopharma 7Pharmaceutical 7+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 49–72 of 132
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B
Abata Therapeutics
August 2024

Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.

Biotechnology · CambridgeCorporate Round
Autobahn Therapeutics
July 2024

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Biotechnology · San Diego$100.0M Series C
LENZ Therapeutics
July 2024

LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.

Health Care · Del Mar$30.0M Post-IPO Equity
Mereo Biopharma
June 2024

Mereo is a new UK-based speciality biopharmaceutical company.

Biopharma · London$50.0M Post-IPO Equity
Notch Therapeutics
June 2024

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.

Biotechnology · Toronto$15.5M Venture - Series Unknown
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post-IPO Equity
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
Nkarta Therapeutics
March 2024

Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.

Biotechnology · South San Francisco$240.0M Post-IPO Equity
Fluent BioSciences
March 2024

Fluent Biosciences, a life science company, offering a molecular analysis of cells without the use of complex microfluidic instrumentation.

Biotechnology · WatertownGrant
Attralus
February 2024

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Biopharma · San Francisco$56.0M Series B
Hookipa Pharma
December 2023

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.

Biotechnology · New York$14.4M Post-IPO Equity
Syros Pharmaceuticals
December 2023

Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.

Biotechnology · Watertown$45.0M Post-IPO Equity
SpringWorks Therapeutics
December 2023

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

Biopharma · Stamford$275.0M Post-IPO Equity
Arcellx
November 2023

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Biopharma · Redwood City$200.0M Post-IPO Equity
Eyebiotech
November 2023

Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.

Biotechnology · New York$65.0M Series A
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
HilleVax
September 2023

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.

Biopharma · Boston$100.0M Post-IPO Equity
Tentarix Biotherapeutics
September 2023

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.

Biotechnology · San Diego$35.0M Series B
Gossamer Bio
July 2023

Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.

Biotechnology · San Diego$212.0M Post-IPO Equity
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post-IPO Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
ElevateBio
May 2023

ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.

Alternative Medicine · Waltham$401.0M Series D

Where Samsara BioCapital invests

Biotechnology23
Health Care14
Therapeutics9
Medical8
Biopharma7
Pharmaceutical7

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?▸

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?▸

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 16 different industry categories.

What is Samsara BioCapital's largest investment?▸

Among tracked funding rounds, ElevateBio received $401.0M in a Series D round. Samsara BioCapital's total known invested capital is $14.2B.

What is the average investment size for Samsara BioCapital?▸

Samsara BioCapital's average investment size is $107.7M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?▸

Recent Samsara BioCapital portfolio additions include Pathalys Pharma, Abata Therapeutics, Autobahn Therapeutics, LENZ Therapeutics, Mereo Biopharma. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →